

Dab/Tram (dabrafenib and trametinib)

## PRELIMINARY SCORE

### CURATIVE



### NON-CURATIVE



## ADJUSTMENTS

### Quality of life



Not qualified for an ESMO-MCBS credit



### Serious and disabling adverse effects



More serious and disabling adverse events observed



### Other adjustments



Dab/Tram (dabrafenib and trametinib)

## SCORE

### CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

### NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response



Overall Survival / Disease-Free Survival / Pathological Complete Response

### INFORMATION

Tumour type: Thoracic Malignancies

Therapeutic Indication: Advanced NSCLC with a BRAF V600 mutation

Experimental Arm: Dab/Tram (dabrafenib and trametinib)

Control Arm: Single arm



